You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
High-Power, Continuous-Wave 3.0- to 3.5-Micron Emitting Quantum Cascade Semiconductor Laser
SBC: INTRABAND, LLC Topic: N12AT003The technical objective of this proposal is to demonstrate a Quantum Cascade Laser (QCL) emitting in the 3.0-3.5 & #181;m wavelength region, which employs a metamorphic buffer layer (MBL). It is the goal of this program to develop a QCL single-stripe device which will operate in a single, diffraction-limited lobe under room temperature continuous-wave (CW) operation to moderately high (~ 0.5 W) ou ...
STTR Phase II 2014 Department of DefenseNavy -
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
CMV Vectored Herpes Simplex Vaccine
SBC: TOMEGAVAX, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors in the development of a therapeutic vaccine against herpes simplex virus 2 (HSV-2), the causative agent of genital herpes. HSV-2 is widely prevalent in the population causing recurrent genital lesions and significantly increasing the risk for other sexually transmitted diseases such a ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget
SBC: DOTY SCIENTIFIC, INC. Topic: NIA? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing a Novel eHealth Application for Oral Systemic Issues during Pregnancy
SBC: InterVision Media Topic: NIDCRDESCRIPTION (provided by applicant): Oral disease is a silent epidemic because of its prevalence and missed prevention opportunities. Evidence has established connections between oral-systemic etiologies, including the effects of periodontal disease (PD), and a range of health outcomes and co-morbidities across the lifecourse (e.g., adverse pregnancy and birth outcomes; early childhood carries; ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Rapid Screening Assay for Novel Epigenetic Drugs
SBC: NZUMBE INC Topic: NIEHSDESCRIPTION (provided by applicant): A hallmark of virtually every cancer is aberrant epigenetic silencing of vital genes required for a normal cell cycle and genome stability (e.g. MLH1, BRCA1, VHL, p16, etc.). Loss of expression of these tumor suppressorgenes plays a critical role in cancer formation and growth. Thus, targeting this root cause of cancer has significant potential to treat and pot ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Chitosan Endoluminal Hemostatic Dressing
SBC: HemCon Medical Technologies Inc Topic: 400DESCRIPTION provided by applicant Perioperative hemorrhage remains the major complication of transurethral and open prostatic surgical procedures Significant blood loss from these procedures causes delayed healing and longer hospitalization which significantly increases the cost of patient care Moreover prolonged urethral catheterization due to significant post operative hematuria is one of ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
A Rapid assay for RNA targeted drugs: Instrumentation Supplement
SBC: NUBAD LLC Topic: 300DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II
SBC: BITE TECHNOLOGIES, LLC Topic: 300DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Preclinical development of novel small molecule malaria drugs that overcome drug
SBC: DESIGNMEDIX, INC. Topic: NIAIDDESCRIPTION provided by applicant The worldwide health problem created by malaria has been made more difficult by the spread of drug resistant parasites We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine resistant and chloroquine sensitive malaria This project carries on preclinical development of a drug candidate that has been select ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health